中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(8): 1836-1840

Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2021.08.018

  • The First Hospital of Changsha, Changsha 410000, China

  • Received Date: 2020-12-01
  • Accepted Date: 2021-02-03
  • Published Date: 2021-08-20
    Abstract
  •   Objective  To systematically evaluate the difference in recurrence-free survival rate, hepatocellular carcinoma (HCC) recurrence rate, all-cause mortality rate, and liver-related mortality rate between hepatitis C-related HCC patients receiving oral direct-acting antiviral (DAA) and those receiving non-DAA (NDAA) treatment regimen.  Methods  CNKI, Wanfang Data, VIP, CBM, PubMed, Embase, and Cochrane Library were searched for Cohort studies of DAA in the treatment of hepatitis C-related HCC patients published before December 2020, and quality assessment and meta-analysis were performed.  Results  A total of 10 cohort studies were included in this study, with 3108 patients in total. The meta-analysis showed that compared with NDAA regimen, DAA treatment significantly increased recurrence-free survival rate (risk ratio [RR]=1.38, 95% confidence interval [CI]: 1.10-1.72, P=0.005) and significantly reduced HCC recurrence rate (RR=0.52, 95%CI: 0.42-0.63, P < 0.000 01), all-cause mortality rate (RR=0.42, 95%CI: 0.32-0.55, P < 0.000 01), and liver-related mortality rate (RR=0.37, 95%CI: 0.18-0.76, P=0.007) in hepatitis C-related HCC patients.  Conclusion  DAA treatment is beneficial and safe for hepatitis C-related HCC patients.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    HOYOS S, ESCOBAR J, CARDONA D, et al. Factors associated with recurrence and survival in liver transplant patients with HCC—a single center retrospective study[J]. Ann Hepatol, 2015, 14(1): 58-63. DOI: 10.1016/S1665-2681(19)30801-4.
    [2]
    MCCLUNE AC, TONG MJ. Chronic hepatitis B and hepatocellular carcinoma[J]. Clin Liver Dis, 2010, 14(3): 461-476. DOI: 10.1016/j.cld.2010.05.009.
    [3]
    SHI K, ZHANG Q, LI YX, et al. Research advances in the risk prediction models for chronic hepatitis B-related hepatocellular carcinoma[J]. J Clin Hepatol, 2020, 36(10): 2315-2319. DOI: 10.3969/j.issn.1001-5256.2020.10.034.

    时克, 张群, 李玉鑫, 等. 慢性乙型肝炎相关肝细胞癌风险预测模型的研究进展[J]. 临床肝胆病杂志, 2020, 36(10): 2315-2319. DOI: 10.3969/j.issn.1001-5256.2020.10.034.
    [4]
    ZHOU JL, YOU H. Accurate prediction of clinical endpoints of liver cirrhosis[J]. J Clin Hepatol, 2020, 36(9): 1921-1922. DOI: 10.3969/j.issn.1001-5256.2020.09.001.

    周家玲, 尤红. 肝硬化临床终点事件的精准预测[J]. 临床肝胆病杂志, 2020, 36(9): 1921-1922. DOI: 10.3969/j.issn.1001-5256.2020.09.001.
    [5]
    SHEN ZX, LI M, ZHANG JM, et al. Etiologies and clinical features of liver cirrhosis in Lanzhou, China[J]. J Clin Hepatol, 2020, 36(4): 783-787. DOI: 10.3969/j.issn.1001-5256.2020.04.015.

    沈自雄, 李敏, 张嵴明, 等. 兰州地区肝硬化的病因构成及临床特征分析[J]. 临床肝胆病杂志, 2020, 36(4): 783-787. DOI: 10.3969/j.issn.1001-5256.2020.04.015.
    [6]
    KEW MC. Prevention of hepatocellular carcinoma[J]. Ann Hepatol, 2010, 9(2): 120-132. DOI: 10.7326/0003-4819-141-1-200407060-00026.
    [7]
    ZEUZEM S. Treatment of chronic hepatitis C virus infection in patients with cirrhosis[J]. J Viral Hepat, 2000, 7(5): 327-334. DOI: 10.1046/j.1365-2893.2000.00229.x.
    [8]
    HOU YH, LIU TF, ZHAO XQ, et al. Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis[J]. J Clin Hepatol, 2020, 36(1): 84-87. DOI: 10.3969/j.issn.1001-5256.2020.01.019.

    侯艺辉, 刘腾飞, 赵晓青, 等. 不同直接抗病毒药物方案对基因1b型慢性丙型肝炎及代偿期丙型肝炎肝硬化临床结局的影响[J]. 临床肝胆病杂志, 2020, 36(1): 84-87. DOI: 10.3969/j.issn.1001-5256.2020.01.019.
    [9]
    ZHANG YD, ZHANG YR, WANG H, et al. Clinical features of hepatitis C patients with failure or recurrence after treatment with pegylated interferon-α combined with ribavirin and the clinical effect of direct-acting antiviral agents[J]. J Clin Hepatol, 2019, 35(11): 2456-2460. DOI: 10.3969/j.issn.1001-5256.2019.11.014.

    张耀弟, 张月荣, 王慧, 等. 聚乙二醇干扰素α联合利巴韦林治疗丙型肝炎失败和复发患者的临床特征及直接抗病毒药物疗效观察[J]. 临床肝胆病杂志, 2019, 35(11): 2456-2460. DOI: 10.3969/j.issn.1001-5256.2019.11.014.
    [10]
    ROCHE B, COILLY A, DUCLOS-VALLEE JC, et al. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC[J]. Liver Int, 2018, 38(Suppl 1): 139-145. DOI: 10.1111/liv.13659.
    [11]
    WARZYSZYN'SKA K, JONAS M, WASIAK D, et al. Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment - preliminary report[J]. Clin Exp Hepatol, 2017, 3(4): 194-197. DOI: 10.5114/ceh.2017.71483.
    [12]
    SINGAL AG, RICH NE, MEHTA N, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma[J]. Gastroenterology, 2019, 157(5): 1253-1263.e2. DOI: 10.1053/j.gastro.2019.07.040.
    [13]
    CABIBBO G, CELSA C, CALVARUSO V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients[J]. J Hepatol, 2019, 71(2): 265-273. DOI: 10.1016/j.jhep.2019.03.027.
    [14]
    KAMP WM, SELLERS CM, STEIN S, et al. Impact of direct acting antivirals on survival in patients with chronic hepatitis C and hepatocellular carcinoma[J]. Sci Rep, 2019, 9(1): 17081. DOI: 10.1038/s41598-019-53051-2.
    [15]
    PREDA CM, BAICUS C, SANDRA I, et al. Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy[J]. United European Gastroenterol J, 2019, 7(5): 699-708. DOI: 10.1177/2050640619841254.
    [16]
    DANG H, YEO YH, YASUDA S, et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both East and West[J]. Hepatology, 2020, 71(6): 1910-1922. DOI: 10.1002/hep.30988.
    [17]
    KUO YH, WANG JH, CHANG KC, et al. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment[J]. Invest New Drugs, 2020, 38(1): 202-210. DOI: 10.1007/s10637-019-00870-9.
    [18]
    ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts[J]. J Hepatol, 2016, 65(4): 734-740. DOI: 10.1016/j.jhep.2016.05.045.
    [19]
    IKEDA K, KAWAMURA Y, KOBAYASHI M, et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma[J]. Dig Dis Sci, 2017, 62(10): 2932-2942. DOI: 10.1007/s10620-017-4739-z.
    [20]
    OCHI H, HIRAOKA A, HIROOKA M, et al. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria[J]. J Gastroenterol, 2021, 56(1): 90-100. DOI: 10.1007/s00535-020-01747-y.
    [21]
    DASH S, AYDIN Y, WIDMER KE, et al. Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment[J]. J Hepatocell Carcinoma, 2020, 7: 45-76. DOI: 10.2147/JHC.S221187.
    [22]
    LI Q, HUANG YX, CHEN L. Research progress in anti-HCV therapeutic regimens without interferon[J]. J Clin Hepatol, 2016, 32(1): 169-173. DOI: 10.3969/j.issn.1001-5256.2016.01.037.

    李强, 黄玉仙, 陈良. 无干扰素抗HCV方案的研究进展[J]. 临床肝胆病杂志, 2016, 32(1): 169-173. DOI: 10.3969/j.issn.1001-5256.2016.01.037.
    [23]
    NAVEED M, ALI A, SHEIKH N, et al. Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs[J]. APMIS, 2020, 128(4): 326-334. DOI: 10.1111/apm.13024.
    [24]
    XU YW, LI W, CHEN JL. Clinical research on direct antiviral drugs and hepatocellular carcinoma[J/CD]. Chin J Liver Dis(Electronic Edition), 2020, 12(2): 37-41. DOI:10.3969/j.issn.1674-7380.2020.02.007.

    许雅文, 李威, 陈京龙. 直接抗病毒药物与肝细胞癌临床研究新进展[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(2): 37-41. DOI:10.3969/j.issn.1674-7380.2020.02.007.
    [25]
    MARTÍNEZ-CAMPRECIÓS J, BONIS PUIG S, PONS DELGADO M, et al. Transient elastography in DAA era. Relation between post-SVR LSM and histology[J]. J Viral Hepat, 2020, 27(4): 453-455. DOI: 10.1111/jvh.13245.
    [26]
    BRUNO S, DI MARCO V, IAVARONE M, et al. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response[J]. Liver Int, 2017, 37(10): 1526-1534. DOI: 10.1111/liv.13452.
    [27]
    CONTI F, BUONFIGLIOLI F, SCUTERI A, et al. Early occurrence and recurrence of hepatocellular carcinomain HCV-related cirrhosis treated with direct-acting antivirals[J]. J Hepatol, 2016, 65(4) : 727-733. DOI: 10.1016/j.jhep.2020.03.030.
    [28]
    REIG M, MARIÑO Z, PERELLÓ C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J]. J Hepatol, 2016, 65(4): 719-726. DOI: 10.1016/j.jhep.2016.04.008.
    [29]
    RAVI S, AXLEY P, JONES D, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis[J]. Gastroenterology, 2017, 152(4): 911-912. DOI: 10.1053/j.gastro.2016.12.021.
    [30]
    KOSTADINOVA L, SHIVE CL, ZEBROWSKI E, et al. Soluble markers of immune activation differentially normalize and selectively associate with improvement in AST, ALT, albumin, and transient elastography during IFN-free HCV therapy[J]. Pathog Immun, 2018, 3(1): 149-163. DOI: 10.20411/pai.v3i1.242.
    [31]
    PERSICO M, ROSATO V, AGLITTI A, et al. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis[J]. Antivir Ther, 2018, 23(2): 129-138. DOI: 10.3851/IMP3186.
    [32]
    DONINI LM, BUSETTO L, BAUER JM, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review[J]. Clin Nutr, 2020, 39(8): 2368-2388. DOI: 10.1016/j.clnu.2019.11.024.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (658) PDF downloads(52) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return